DistantNews
🇬🇧 United Kingdom /Health & Science

UK regulator censures HRT provider Theramex for 'systemic failures' endangering patients

From The Guardian · (1d ago) English Critical tone

Translated from English, summarized and contextualized by DistantNews.

TLDR

  • Theramex, a major UK producer of HRT drugs, has been censured by the Prescription Medicines Code of Practice Authority (PMCPA) for systemic failures in patient safety.
  • The company failed to update crucial prescribing information for years and did not clearly state that certain drugs must not be used during pregnancy, leading to 21 breaches of the pharmaceutical industry's code of practice.
  • Theramex has also left the UK's self-regulatory framework, prompting the MHRA to assure that it will take necessary steps to ensure patient safety despite the company's departure from the PMCPA.

The UK's pharmaceutical industry is facing scrutiny following a severe reprimand against Theramex by the Prescription Medicines Code of Practice Authority (PMCPA). This self-regulatory body, tasked with upholding industry standards, found Theramex guilty of "systemic failures" that jeopardized patient safety. The company's negligence in updating vital prescribing information for hormone replacement therapy (HRT) drugs like Evorel and Intrarosa, and failing to clearly warn about contraindications during pregnancy, represents a significant breach of trust.

systemic failures

— RegulatorsDescribing the breaches found at Theramex.

Whistleblowers within Theramex alerted the PMCPA to these "alarming" compliance issues, highlighting a critical lapse in oversight. The scale of the problem is underscored by the fact that Evorel patches are among the most prescribed HRT forms in the UK, with hundreds of thousands of prescriptions issued annually. The PMCPA's findings reveal 21 breaches of the Association of the British Pharmaceutical Industry (ABPI) code of practice, bringing discredit upon the entire pharmaceutical sector.

jeopardise patient safety

— RegulatorsDescribing the impact of Theramex's failures.

Adding to the concern, Theramex has opted to leave the PMCPA's jurisdiction, a move that the PMCPA itself described as delaying regulatory action. While the Medicines and Healthcare products Regulatory Agency (MHRA) has assured the public that it possesses the legal powers to investigate and act on safety concerns, the company's departure from self-regulation is a worrying development. Dr. Amit Aggarwal of the ABPI expressed disappointment, noting that Theramex has fallen "seriously short of the standards expected" and that leaving the self-regulatory system bypasses standards above and beyond legal requirements.

alarming compliance issues and incomplete prescribing information

— RegulatorsDetailing the concerns raised by whistleblowers.

From a UK perspective, this incident raises serious questions about the effectiveness of industry self-regulation and the accountability of pharmaceutical companies. While the MHRA's intervention provides a degree of reassurance, the fact that such widespread failures occurred and that the company has sought to distance itself from oversight is deeply concerning for patient safety and public confidence in the healthcare system. The emphasis on patient safety and the rigorous standards expected within the UK's pharmaceutical sector are paramount, and this case highlights the need for continued vigilance and robust regulatory action.

brought discredit upon, and reduced confidence in, the pharmaceutical industry

— PMCPAOn the impact of Theramex's breaches.
DistantNews Editorial

Originally published by The Guardian in English. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog